Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Novo ...

Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...

Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the company ramps up efforts to ...

Danish pharma major Novo Nordisk has announced an investment of $1.1 billion to expand its production facility in Brazil’s ...

The Danish pharmaceutical company behind obesity drug Wegovy, Novo Nordisk, plans to invest US$1.09bn in expanding its ...

Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity now is under attack on multiple fronts, from ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

StockNews.com upgraded shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a strong-buy rating in a research report sent to investors on Monday morning. Other research analysts ...

India's anti-obesity drug market shows significant growth. It has increased fourfold in five years. Lifestyle diseases and ...

Both of these products will be available in Europe ... constitute significant milestones for Novo Nordisk and the treatment of diabetes. We look forward to making Tresiba and Ryzodeg available ...

India's anti-obesity drug market has surged, growing over fourfold in five years, reaching ₹576 crore by March 2025, driven ...